Now showing items 1-2 of 2

    • Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis 

      Berry, James Dale; Shefner, Jeremy M.; Conwit, Robin; Schoenfeld, David Alan; Keroack, Myles; Felsenstein, Donna; Krivickas, Lisa; David, William Samuel; Vriesendorp, Francine; Pestronk, Alan; Caress, James B.; Katz, Jonathan; Simpson, Ericka; Rosenfeld, Jeffrey; Pascuzzi, Robert; Glass, Jonathan; Rezania, Kourosh; Rothstein, Jeffrey D.; Greenblatt, David J.; Cudkowicz, Merit Ester (Public Library of Science, 2013)
      Objectives: Ceftriaxone increases expression of the astrocytic glutamate transporter, EAAT2, which might protect from glutamate-mediated excitotoxicity. A trial using a novel three stage nonstop design, incorporating Phases ...
    • Distinct plasma immune signatures in ME/CFS are present early in the course of illness 

      Hornig, M.; Montoya, J. G.; Klimas, N. G.; Levine, S.; Felsenstein, Donna; Bateman, L.; Peterson, D. L.; Gottschalk, C. G.; Schultz, A. F.; Che, X.; Eddy, M. L.; Komaroff, Anthony L.; Lipkin, W. I. (American Association for the Advancement of Science (AAAS), 2015)
      Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an unexplained incapacitating illness that may affect up to 4 million people in the United States alone. There are no validated laboratory tests for diagnosis ...